newsletter published in partnership between TMIC and
the Metabolomics Society
Issue 30 - February 2014
Metabolomics Society News
|| Founder &
Managing Director of Metabolomic Discoveries GmbH,
Dr. Nicolas Schauer is founder and managing director of Metabolomic Discoveries GmbH, a comprehensive metabolomics service and biomarker research company based in Golm, Germany. He has a track-record of over ten years in metabolomics. He started his first metabolomics work in 2003 at the Max-Planck-Institute of Molecular Plant Physiology. He is author of many high-ranking and peer-reviewed articles, as well as book chapters. In 2009 he established the only independent metabolomics company in the world in order to provide his expertise to the market. The company has focused on multi-parallel high-resolution and accurate mass, untargeted metabolomics using state-of-the art mass spec technology. The established technology platform provides methods of global metabolomics, lipidomics, volatile profiling and fingerprinting. All of the metabolomics approaches, such as biomarker identification, fluxomics, and network modelling are used to study cellular processes, disease mechanisms and onset, as well as gene and metabolite functions in clinical studies and experimental research.
Increasingly, researchers are relying on metabolomics to uncover sensitive disease biomarkers. In this paper, the investigators utilized metabolomic profiling to gain insight into multiple sclerosis (MS) biomarkers and pathogenesis. Using 800 MHz proton nuclear magnetic resonance (NMR), they sought to identify metabolite markers that would allow them to differentiate between MS and non-MS patients. They analyzed cerebrospinal fluid (CSF) samples from 15 MS patients and 17 non-MS patients. As a result of this study, they identified a number of statistically significant metabolites. While the research team found increased levels of choline, myo-inositol, and threonate in MS patients, it also found decreased levels of 3-hydroxybutyrate, citrate, phenylalanine, 2-hydroxyisovalerate, and mannose in the same patients. As this work demonstrates, these metabolites may prove to be useful as biomarkers for MS and shed light on MS pathogenesis.
Bipolar disorder (BD) is a debilitating and widespread mental disorder. There is a need for reliable biomarkers for the diagnosis of BD. In this study, the research team sought to use a gas chromatography-mass spectrometry (GC-MS) based metabonomic approach to differentiate between BD patients and healthy control subjects. Combined with multivariate statistical analysis, they identified 37 urine metabolites from the above two patient groups and were able to distinguish between the two groups. In particular, 2,4-dihydroxypyrimidine stood out as an effective biomarker for BD. This study has helped to advance the development of a urine-based diagnostic test for BD.
|1 Feb 2014
A metabolic biosignature of early response to anti-tuberculosis treatment
The successful treatment of tuberculosis (TB) requires long-term multidrug chemotherapy. Clinical trials to evaluate new drugs and regimens for TB treatment are protracted due to the slow clearance of Mycobacterium tuberculosis (Mtb) infection and the lack of early biomarkers to predict treatment outcome.
Advancements in the field of metabolomics make it possible to identify metabolic profiles that correlate with disease states or successful chemotherapy. However, proof-of-concept of this approach has not been provided for a TB-early treatment response biosignature (TB-ETRB).
Methods: Urine samples collected at baseline and during treatment from 48 Ugandan and 39 South African HIV-seronegative adults with pulmonary TB were divided into discovery and qualification sets, normalized to creatinine concentration, and analyzed by liquid chromatography-mass spectrometry to identify small molecule molecular features (MFs) in individual patient samples.
A biosignature that distinguished baseline and 1 month treatment samples was selected by pairwise t-test using data from two discovery sample sets. Hierarchical clustering and repeated measures analysis were applied to additional sample data to down select molecular features that behaved consistently between the two clinical sites and these were evaluated by logistic regression analysis.
Results: Analysis of discovery samples identified 45 MFs that significantly changed in abundance at one month of treatment.
Down selection using an extended set of discovery samples and qualification samples confirmed 23 MFs that consistently changed in abundance between baseline and 1, 2 and 6 months of therapy, with 12 MFs achieving statistical significance (p <0.05). Six MFs classified the baseline and 1 month samples with an error rate of 11.8%.
Conclusions: These results define a urine based TB-early treatment response biosignature (TB-ETRB) applicable to different parts of Africa, and provide proof-of-concept for further evaluation of this technology in monitoring clinical responses to TB therapy.
|8 Jan 2014
Global Metabolomics Market Report 2013 - Forecasts to 2017
Research and Markets has announced the addition of the "Global Metabolomics Market Report 2013 - Forecasts to 2017" report to their offering.
Over the last decade, genomics and proteomics have been used as key tools to discover potential drug targets and to better understand the complexities of biology. To balance research in these areas, metabolomics, a new science is evolving for analyzing the basic metabolic changes taking place in a living organism. Metabolomics is thus an emerging concept which refers to the systematic study of the distinctive chemical fingerprints generated in a particular cellular process.
Metabolomics Market - Analysis of Global Technology, Application Trends and Landscape 2012-2017 report covers the market by disease indications along with the applications and metabolite profiling for biomarker discovery applications. In addition, it also includes the factors driving and restraining the market and covers the market scenario in the U.S., Europe, Asia and the Rest of the World (ROW). This report will provide the company profiles of key companies along with the competitive analysis.
The Global Metabolomics market is showing a double digit growth (CAGR 35%) due to supportive factors such as, (i) increased willingness of biotechnology and pharma companies to adopt metabolomics concept to drive R&D activity within the industry, (ii) rapid growth of metabolomics data analysis softwares and solutions, and (iii) the advancement of analytical technologies. Metabolomics is used in the identification of new biomarkers, which indicate a change in the physiological state of a cell or tissue. Biomarker screening is important in the process of new drug discovery, and is also a key in vitro diagnostics tool. Additionally it is also being used for environmental toxicology screening. While, there are major concerns of this market such as the validation challenges, the positive aspects may very well offset the market restraints to aid the market grow at an exceptional rate.
The report also profiles leading participants of this industry with their recent developments and other strategic industry activities. These include: Metabolon Inc (U.S.), Metanomics (Germany), Metabolomic Technologies Inc. (U.S.), Human Metabolome Technologies (Japan), Beckman Coulter (U.S.), Agilent Technologies Inc (U.S.), Bruker Corporation (U.S.), Waters Corporation (U.S.), Biocrates Lifesciences (Austria), Chenomx Inc (Canada), Eisai co. ltd (Japan), Nextgen Metabolomics (U.S.), Phenomenome Discoveries Inc. (Canada) and Metabolomic Discoveries (Germany).
Source: PR Newswire
|7 Jan 2014
SRI Wins $4.5M NHLBI Contract to Create Metabolomics Center
SRI International on Monday said that the National Heart, Lung, and Blood Institute awarded it a $4.5 million contract to establish a center aimed at improving metabolomics research.
Under the terms of the contract, SRI will create the Metabolite Standards Synthesis Center to prepare molecules for use by researchers. Metabolomics offers promise as a technology for detecting and monitoring disease progression, as well as response to therapeutics, SRI said, adding it can help stratify patients and identify new biomarkers and drug targets. But one bottleneck faced by researchers has been an inability to access metabolite standards needed to confirm and quantify their results.
"Currently, more than half of all human metabolites are unavailable, and many metabolites have never been synthesized, or their structures have only been speculated, and therefore these important molecules are not available to researchers," Mary Tanga, director of the Center for Chemical Biology in SRI Biosciences and principal investigator of SRI's Metabolite Standards Synthesis Center, said in a statement. "Researchers can pursue the answers to important questions if they actually have the compounds. The reference standards that SRI scientists will synthesize are critical to advances in metabolomics."
The new center will create a library of thousands of metabolites to be made available to the scientific community. Synthesized metabolites will serve as standards for research, help improve the understanding of disease processes, elucidate new disease biomarkers, and provide new methods to monitor therapeutic outcomes, SRI said.
Researchers can submit a request for compound synthesis to the Metabolomics Workbench. SRI will prepare the material upon NIH approval.
The NHLBI contract is part of a program developed by the NIH Common Fund Metabolomics Program, which seeks to increase metabolomics research capacity in the US by supporting infrastructure expansion, training, technology development, and reference standards synthesis.
|3-5 Feb 2014
Applications of NMR in Industry Conference
|3-7 Feb 2014
The Imperial International
Phenome Training Centre is offering "Hands-on
LC-MS for Metabolic Profiling"
|2 March 2014
Metabolomics course at the upcoming Pittcon
information, please visit the Pittcon
|6 March 2014
MzTab for Metabolomics
|17-21 Mar 2014
EMBO Practical Course on
Metabolomics Bioinformatics for Life
This course will provide an overview of key issues that affect metabolomics studies, bioinformatics tools, and procedures for the analysis of metabolomics data. It will be delivered using a mixture of lectures, computer-based practical sessions and interactive discussions. The course will provide a platform for discussion of the key questions and challenges in the field of metabolomics.
This course is aimed at PhD students and researchers with a minimum of one year’ s experience in the field of metabolomics who are seeking to improve their skills in metabolomics data analysis. Participants must have experience using R (including a basic understanding of the syntax and ability to manipulate objects) and the UNIX/LINUX operating system.
For more information, visit http://www.ebi.ac.uk/training/course/metabolomics-2014.
|18-21 Mar 2014
Singapore Lipid Symposium
The Singapore Lipid Symposium (biennial, since 2006) has rapidly evolved into a key event to keep up to date for novel developments in lipidomics in Asia Pacific. Based on past experience, we are expecting participation of approximately 150-200 from around the world and representation from a wide range of areas in the life sciences across academia and industry. The official launch of a new network dedicated to deciphering lipidomics variations will be a major first highlight, followed by community building workshops and the main symposium session.
For more details, please visit http://www.lipidprofiles.com/index.php?id=82
|7-11 Apr 2014
Workshop Metabolomics 2014
|30 Apr 2014
Analytical Tools for
Cutting-edge Metabolomics - a joint meeting of
the Analytical Division of the RSC and the
international Metabolomics Society
Analytical chemistry has been one of the driving forces behind the development of metabolomics research over the past decade. The conference will bring together exceptional scientists for a program consisting of plenary and invited talks, posters, as well as an oral session devoted to early career researchers. It will be an excellent opportunity for analytical chemists to learn more about metabolomics and its application, and for metabolomics scientists to improve their knowledge of cutting-edge bioanalytical tools.
Deadline for submission of abstracts: 14 March 2014
Prof. Jeremy Nicholson, Imperial College, London UK - Plenary speaker
Dr Julian Griffin, MRC Human Nutrition Research, Cambridge, UK
Prof. Roy Goodacre, University of Manchester, UK
Prof. Jean-Luc Wolfender, University of Geneva, Switzerland
Dr Steffen Neumann, Leibniz Institute of Plant Biochemistry, IPB Halle, Germany
Prof Paul Thomas, Loughborough University
|19-21 May 2014
8e Journées Scientifiques
du Réseau Français de Métabolomique et
The Amiens RFMF Congress (7 JS RFMF) took place in 2013 due to the generous support of Picardie Jules Verne University and various corporations. This event featured three keynote speakers, Age Smilde, Amsterdam, The Netherlands; Joachim Kopka, Golm-Postdam, Germany and Reza Salek, Cambridge, UK presenting state-of-the-art topics for metabolomics. This event was very successful, with 162 attendees from 75 public and private laboratories, 59 high-quality scientific presentations, 4 workshops and 6 industrial seminars. Four conferences, one workshop and one industrial seminar were held in English. The 2013 event gave an opportunity to gauge the strength and dynamic qualities of the French or French-speaking metabolomics and fluxomics community.
The 8th RFMF Congress will take place in Lyon (Eastern France) in May 19-21, 2014. The Metabolomic Community of the Lyon and Rhône-Alpes Region laboratories is the local organizer of the 2014 edition.
The key topics, chosen by Lyon metabolomics community, for the 8th RFMF Congress are:
The 8th RFMF Congress will include several workshops, one of them dealing with the Galaxy platform (workflow for metabolomics), one dealing with “Sample preparation for metabolomics study”, and a third one with “MetaboLights and COSMOS initiative”.
RFMF is generously supporting the attendance of students or post-docs (under 35 years old) at The 8th RFMF Congress Lyon 2014 through the provision of travel grants (up to €1000 for overseas applicants).
For more information on the 8th RFMF Congress, please visit https://colloque.inra.fr/8_js_rfmf_lyon_2014
|16-17 Jun 2014
Informatics and Statistics
for Metabolomics (2014)
A poster announcing this workshop can be found here.
The workshop will cover many topics ranging from understanding metabolomics technologies, data collection and analysis, using pathway databases, performing pathway analysis, conducting univariate and multivariate statistics, working with metabolomic databases and exploring chemical databases. Participants will be given various data sets and short assignments to assist with the learning process.
This course is intended for graduate students, post-doctoral fellows, clinical fellows and investigators who are interested in learning about both bioinformatic and cheminformatic tools to analyze and interpret metabolomics data.
Prerequisite: Your own laptop computer. Minimum requirements: 1024x768 screen resolution, 1.5GHz CPU, 1GB RAM, recent versions of Windows, Mac OS X or Linux (Most computers purchased in the past 3-4 years likely meet these requirements). If you do not access to a laptop, you may loan one from the CBW. Please contact firstname.lastname@example.org for more information.
Pre-Readings: You are expected to have completed the following tutorials in R beforehand. The tutorial should be very accessible even if you have never used R before. Please complete the following: R Tutorial
|23-26 Jun 2014
Metabolomics 2014: 10th
Annual International Conference of the
We are delighted to host the 10th Anniversary of the International Conference of the Metabolomics Society (Metabolomics2014) at Keio University in Tsuruoka City, where the very first meeting of the society was held in 2005. Since then, Tsuruoka has grown to “a city of metabolomics”; various additional research buildings have been built, and two spin-out companies established. Tsuruoka is a pretty city located 500 km north of Tokyo (about 1 hour flight), and surrounded by beautiful Japanese nature, historic spots, and exotic culture. You will also enjoy the best authentic Japanese food and sake (rice wine), as well as hot springs. So, come celebrate the 10th anniversary of the society, and enjoy high-quality scientific presentations by top-notch researchers around the world.
Early registration and abstract submission due March 31, 2014.
For detailed information about Metabolomics 2014, visit http://metabolomics2014.org.
|10-12 Sep 2014
Call for Papers
If you would like to be considered for an oral presentation at this meeting, Submit an abstract for review now!
Oral Presentation Submission Deadline: 31 January 2014
Call for Posters
You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!
Poster Submission Deadline: 27 August 2014
Drug Discovery and Pharma
Human Health and Nutrition
Microbial, Invertebrate and Environmental Applications
Data Analysis and Integration with Systems Biology
For more details, please visit the conference website.
|29-30 Oct 2014||
Clinical Applications of
As the analytical power of mass spec is realised, the range of applications using this technology continues to expand. Focus at this meeting will be given to both traditional & emerging uses of MS in the clinic. Hot topics to be covered include developments of MS in applications ranging from vitamin D detection to newborn blood spot analysis. Attending this event will provide you with excellent opportunities for networking with like minded peers, helping you to build new relationships and optimise your workflow.
Running alongside the conference will be an exhibition covering the latest technological advances and associated services from leading solution providers within this field. Registered delegates will also have access to the co-located Food Analysis Congress, ensuring a cost effective trip.
For more details, please visit http://selectbiosciences.com/conferences/index.aspx?conf=CAMS2014
|29-30 Oct 2014
Food Analysis Congress
Focus will be given to advances in both the analysis of natural food allergens and toxins, as well as contaminants introduced through processing and packaging. Points for discussion will also include the ongoing issue of food traceability and efforts to reduce food fraud. Attending this event will provide you with excellent opportunities for networking with like minded peers, helping you to find solutions and build collaborations.
Running alongside the conference will be an exhibition covering the latest technological advances and associated services from leading solution providers within this field. Registered delegates will also have access to the co-located Clinical Applications of Mass Spectrometry track, ensuring a cost effective trip.
For more details, please visit http://selectbiosciences.com/conferences/index.aspx?conf=FAC2014
|28 Jun to 2 Jul 2015
Metabolomics 2015: 11th
Annual International Conference of the
Stay abreast of the latest Metabolomics Society news via the Twitter feed on the front page of the website (http://www.metabolomicssociety.org). Also you can follow us on Twitter: Metabolomics Society @MetabolomicsSoc and Metabolomics journal @Metabolomics. And you can visit us on Facebook.
Please come back later for detailed information about Metabolomics 2015 by visiting http://metabolomics2015.org.
This is a resource for
advertising positions in metabolomics. If you have a job
you would like posted in this newsletter, please email
Ian Forsythe (email@example.com).
Job postings will be carried for a maximum of 4
issues (8 weeks) unless the position is filled prior to
|Postdoctoral Scientist in Bioinformatics of Metabolomics||National Institute for Medical Research||London, UK||21-Jan-2014||12-Feb-2014
Institute for Medical Research
|Project Leader Metabolomics||Metabolomic Discoveries GmbH||
|Research Scientist (NMR Spectroscopist to support Business Development group)||Bruker BioSpin||
|Assistant Research Scientist (NMR Spectroscopist to support R&D efforts for Business Development group)||Bruker BioSpin||Billerica, USA||2-Dec-2013||Bruker BioSpin|
Ian J. Forsythe, M.Sc.MetaboNews
Department of Computing Science
University of Alberta
221 Athabasca Hall
Edmonton, AB, T6G 2E8, Canada
This newsletter is published in partnership between The Metabolomics Innovation Centre (TMIC, http://www.metabolomicscentre.ca/) and the Metabolomics Society (http://www.metabolomicssociety.org) for the benefit of the worldwide metabolomics community.
A single source destination for fee-for-service metabolic profiling including comprehensive metabolite identification, quantification, and analysis